Dr Sexl speaks with ecancer at EHA 23 about the findings linking CDK6 to p53 regulation and transcription in AML.

While CDK4/6 inhibitors are being pursued as regulators of the cell cycle in breast and ovarian cancers, Dr Sexl highlights that CDK4 alone is active as a regulator in AML.

Dr Sexl also spoke with ecancer about JAK pathways in B cell lymphoma, coming soon.